Prime Medicine, Inc. (NASDAQ:PRME - Get Free Report)'s share price rose 11.6% on Wednesday . The company traded as high as $6.55 and last traded at $6.55. Approximately 1,478,068 shares traded hands during trading, a decline of 45% from the average daily volume of 2,679,189 shares. The stock had previously closed at $5.87.
Wall Street Analyst Weigh In
A number of equities research analysts have recently commented on PRME shares. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Prime Medicine in a report on Wednesday. Wall Street Zen cut shares of Prime Medicine from a "hold" rating to a "sell" rating in a report on Tuesday, September 2nd. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has a consensus rating of "Sell".
Read Our Latest Analysis on PRME
Prime Medicine Trading Up 14.1%
The stock has a market cap of $901.62 million, a P/E ratio of -4.29 and a beta of 2.65.
About Prime Medicine
(
Get Free Report)
We are a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address the widest spectrum of diseases by deploying our Prime Editing technology, which we believe is a versatile, precise, efficient and broad gene editing technology.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Prime Medicine, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prime Medicine wasn't on the list.
While Prime Medicine currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
